BioCardia, Inc.
BCDA evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for BCDA—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · BCDA
BioCardia, Inc. is a clinical-stage biotechnology company developing autologous and allogeneic cell therapies for cardiovascular and pulmonary diseases, with a lead CardiAMP platform in Phase 3 for ischemic heart failure.
Key risk: Limited cash runway
BioSniper Score
Based on 3 of 6 signals
Limited data coverage
Financial data as of Jun 30, 2026.
Tracking 5 clinical trials for BioCardia, Inc..
BioCardia, Inc. is a clinical-stage biotechnology company developing autologous and allogeneic cell therapies for cardiovascular and pulmonary diseases, with a lead CardiAMP platform in Phase 3 for ischemic heart failure.
- Clinical-stage company developing cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases [sec_mda · as of 2026-03-24].
- Lead program is the CardiAMP autologous mononuclear cell therapy platform, with a Phase 3 pivotal trial completed for ischemic heart failure with reduced ejection fraction (HFrEF) [catalyst · as of 2025-06-01].
- Cash and equivalents of $4.1 million as of 2026-06-30, with a net loss of $1.6 million for the period [sec].
- Company expects to need additional funding, with cash as of December 31, 2025 ($2.5 million) not sufficient to fund planned operations [sec_mda · as of 2026-03-24].
What works
- CardiAMP platform has completed a Phase 3 pivotal trial, a key milestone toward potential regulatory submission [catalyst · as of 2025-06-01].
- The company is advancing both autologous and allogeneic MSC programs, diversifying its pipeline [sec_mda · as of 2026-08-12].
- Preclinical data suggest the cells improve microvascular density and reduce fibrosis, addressing a key mechanism in heart failure [sec_mda · as of 2026-03-24].
What to weigh
- Cash and equivalents of $4.1 million as of 2026-06-30 are limited, and the company has stated that prior cash levels were insufficient to fund operations beyond the near term [sec_mda · as of 2026-03-24].
- The company has generated only modest revenues to date and does not expect revenue from product sales unless and until regulatory approval is obtained [sec_mda · as of 2026-08-12].
- Future capital requirements are uncertain and depend on clinical trial progress, FDA acceptance, and regulatory outcomes [sec_mda · as of 2026-08-12].
- The company may need to raise additional capital on dilutive terms and may be unsuccessful in securing funding [sec_mda · as of 2025-11-12].
From the filings
Quoted directly from source documents.
Company is clinical-stage developing cell therapies for cardiovascular and pulmonary diseases
“We are a clinical-stage company developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases with significant unmet medical needs.”
SEC MD&A · March 24, 2026
Phase 3 pivotal trial completed for CardiAMP in HFrEF
“Phase 3 Topline: Randomized Controlled Pivotal Trial of Autologous Bone Marrow Mononuclear Cells Using the CardiAMP C”
Catalysts · June 1, 2025
Company does not expect revenue until regulatory approval
“We do not expect to generate any revenue from sales of our autologous and allogeneic cell therapy candidates unless and until we obtain regulatory approval.”
SEC MD&A · August 12, 2026
Catalyst timeline
- 2023-08-23 · Phase 2 Start: Phase I/II Clinical Trial of Human Allogenic Culture-expanded Bone Marrow-derived Mesenchymal Stem C — Trial initiated but status is 'Active, not recruiting'; endpoint is treatment-emergent serious adverse events.
- 2025-06-01 · Phase 3 Topline: Randomized Controlled Pivotal Trial of Autologous Bone Marrow Mononuclear Cells Using the CardiAMP C — Trial completed; endpoint is a composite based on Finkelstein-Schoenfeld hierarchical analysis.
- 2025-08-11 · Earnings Report - SEC 8-K filing — Periodic financial filing.
- 2025-11-12 · Earnings Report - SEC 8-K filing — Periodic financial filing.
Risks & what to watch (4)›
Key risks
- Limited cash runway — Cash of $4.1M as of 2026-06-30 may not sustain operations; prior cash was insufficient beyond near term [sec_mda · as of 2026-03-24].
- No revenue from product sales — Company has only modest revenues and expects none until regulatory approval, which is uncertain [sec_mda · as of 2026-08-12].
- Dependence on future funding — Future capital needs depend on trial progress and FDA acceptance; additional funding may be dilutive or unavailable [sec_mda · as of 2026-08-12].
- Clinical and regulatory uncertainty — Outcomes of clinical trials and FDA acceptance of therapies are uncertain and could delay or prevent commercialization [sec_mda · as of 2026-08-12].
What to watch
- Progress and results of the Phase 3 CardiAMP trial for HFrEF, which has completed enrollment [catalyst · as of 2025-06-01].
- Any updates on FDA acceptance or feedback for the CardiAMP and allogeneic MSC programs [sec_mda · as of 2026-08-12].
- Future financing events, including potential equity or debt offerings, given the limited cash runway [sec_mda · as of 2025-11-12].
- Initiation or updates from the Phase 1/2 allogeneic MSC trial (NCT05925608) [catalyst · as of 2023-08-23].
Sources: Catalysts · SEC MD&A · Generated August 25, 2026 · How we verify sources →
Run BioCardia, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available BioCardia, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 3 of 6 signals · derived from public data
No clinical pipeline tracked — this score reflects financial & catalyst signals only.
7.2 months
D/E 0.76
No tracked pipeline phase
No tracked pipeline candidates
No upcoming catalysts tracked
24 buys · 0 sells (180d)
Runway
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
15
Total value held
$756K
| Holder | Shares | Value |
|---|---|---|
| vanguard capital management llc | 249,182 | $302K |
| geode capital management, llc | 94,287 | $114K |
| vanguard fiduciary trust co | 66,270 | $80K |
| citadel advisors llc | 63,384 | $77K |
| susquehanna international group, llp | 38,827 | $47K |
| brown advisory inc | 35,538 | $43K |
| xtx topco ltd | 24,270 | $29K |
| commonwealth equity services, llc | 18,283 | $22K |
| two sigma securities, llc | 14,780 | $18K |
| renaissance technologies llc | 13,900 | $17K |
Showing top 10 of 15 institutional holders of BioCardia, Inc.. Open the full 13F history after sign-in.
Short Interest
as of May 20, 2026- % of float
- 1.8%
- Days to cover
- 2.7
- Shares short
- 165,816
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
BCDA short interestGovernance
Frequently asked questions
What is the AI investment thesis for BioCardia, Inc.?
BioCardia, Inc. is a clinical-stage biotechnology company developing autologous and allogeneic cell therapies for cardiovascular and pulmonary diseases, with a lead CardiAMP platform in Phase 3 for ischemic heart failure.
Who is the CEO of BioCardia, Inc.?
Dr. Peter A. Altman Ph.D. is the chief executive officer of BioCardia, Inc. (BCDA).
Where is BioCardia, Inc. headquartered?
BioCardia, Inc. (BCDA) is headquartered in Sunnyvale, CA, United States.
What therapeutic areas does BioCardia, Inc. focus on?
BioCardia, Inc. develops therapies across Oncology, Gene Therapy, Cardiovascular, Infectious Disease, Respiratory.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.